New Treatment Program May Help Patients With Cancer and Untreated Depression
the Cancer Therapy Advisor take:
According to two studies, one published in The Lancet and the other published in The Lancet Oncology, a new program called Depression Care for People with Cancer (DCPC) significantly improved depression symptoms in patients with cancer.
The program is a systematic treatment program provided by a team of specialist oncology nurses and psychiatrists working simultaneously with the patient's cancer team. The program involves both antidepressants and psychological therapy.
In the study published in The Lancet, researched studied 500 patients with major depressive disorder and cancer with a good prognosis. Patients either received DCPC or standard care, which involves physician support that may prescribe antidepressants or referral to mental health services.
They found that after 6 months, 62% of patients experienced at least a 50% reduction in the severity of their depression versus 17% of patients receiving standard care.
In the study published in The Lancet Oncology, patients with lung cancer and major depression who received DCPC improved the patients' anxiety, daily functioning, and overall quality of life. When patients with cancer have a poor prognosis, depression can ruin what time the patient has left. Treating major depression can significantly improve a patient's life despite a poor prognosis.
Nearly 3/4th of depressed cancer patients do not receive any form of treatment for their depression.
The papers, published in The Lancet Psychiatry, The Lancet and The Lancet Oncology, have examined the prevalence of depression within cancer sufferers and assessed a new program of integrated treatment that could revolutionize the care of depression.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy